All IndicationsOncologyApprovedPhase 3Phase 3Phase 3Phase 2Phase 2
🎗️
Melanoma
7
Companies
8
Drug Programs
3
Phase 3
0
Upcoming PDUFAs
Competitors
REPL
Replimune
Tudriqev
MRNA
Moderna, Inc.
mRNA-4157
BreakthroughFast TrackOrphan Drug
INCY
Incyte Corporation
pembrolizumab + epacadostat
NVS
Novartis AG
Vemurafenib
SGEN
Seagen Inc.
SEA-CD40
INCY
Incyte Corporation
INCAGN02390
MRK
Merck
V940
LLY
Eli Lilly
Replimune melanoma drug
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| REPL Replimune | Tudriqev | Approved | — | — | — |
| MRNA Moderna, Inc. | mRNA-4157 | Phase 3 | BTFTOD | — | — |
| INCY Incyte Corporation | pembrolizumab + epacadostat | Phase 3 | — | — | — |
| NVS Novartis AG | Vemurafenib | Phase 3 | — | — | — |
| SGEN Seagen Inc. | SEA-CD40 | Phase 2 | — | — | — |
| INCY Incyte Corporation | INCAGN02390 | Phase 2 | — | — | — |
| MRK Merck | V940 | — | — | — | — |
| LLY Eli Lilly | Replimune melanoma drug | — | — | — | — |
Development Stage Distribution
Unknown
2
Approved
1
Phase 3
3
Phase 2
2
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.